THE PCCA BLOG
US$ 20.68
gip and glp-1 receptor agonist Dual GIP/GLP-1 agonists: New advances for treating type-2 diabetes π§π΅π² ππ³π³π²π°π πΌπ³ πππ£-π π₯π²π°π²π½ππΌπΏ
Description
Contrave (naltrexone/bupropion): A combination medication targeting appetite and cravings
Comparison of the TLR4/NFB and NLRP3 Signalling Pathways in Major Organs of the Mouse After Intravenous Injection of Lipopolysaccharide
As a board-certified specialist in obesity medicine , Dr
Based on SURMOUNT-1 data analysis, tirzepatide decreased the 10-year estimated risk of ASCVD for obese or overweight patients
No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: a pooled analysis of cardiovascular outcome trials
